Heart failure (HF) and chronic kidney disease (CKD) are two pathological conditions with a high prevalence in the general population. When they coexist in the same patient, a strict interplay between them is observed, such that patients affected require a clinical multidisciplinary and personalized management. The diagnosis of HF and CKD relies on signs and symptoms of the patient but several additional tools, such as blood-based biomarkers and imaging techniques, are needed to clarify and discriminate the main characteristics of these diseases. Improved survival due to new recommended drugs in HF has increasingly challenged physicians to manage patients with multiple diseases, especially in case of CKD. However, the safe administration of these drugs in patients with HF and CKD is often challenging. Knowing up to which values of creatinine or renal clearance each drug can be administered is fundamental. With this review we sought to give an insight on this sizable and complex topic, in order to get clearer ideas and a more precise reference about the diagnostic assessment and therapeutic management of HF and CKD.
Assessment and management of heart failure in patients with chronic kidney disease / A.I. Guaricci, F. Sturdà, R. Russo, P. Basile, A. Baggiano, S. Mushtaq, L. Fusini, F. Fazzari, F. Bertandino, F. Monitillo, M.C. Carella, M. Simonini, G. Pontone, M.M. Ciccone, G. Grandaliano, G. Vezzoli, F. Pesce. - In: HEART FAILURE REVIEWS. - ISSN 1573-7322. - (2023), pp. 1-16. [Epub ahead of print] [10.1007/s10741-023-10346-x]
Assessment and management of heart failure in patients with chronic kidney disease
A. Baggiano;G. Pontone;
2023
Abstract
Heart failure (HF) and chronic kidney disease (CKD) are two pathological conditions with a high prevalence in the general population. When they coexist in the same patient, a strict interplay between them is observed, such that patients affected require a clinical multidisciplinary and personalized management. The diagnosis of HF and CKD relies on signs and symptoms of the patient but several additional tools, such as blood-based biomarkers and imaging techniques, are needed to clarify and discriminate the main characteristics of these diseases. Improved survival due to new recommended drugs in HF has increasingly challenged physicians to manage patients with multiple diseases, especially in case of CKD. However, the safe administration of these drugs in patients with HF and CKD is often challenging. Knowing up to which values of creatinine or renal clearance each drug can be administered is fundamental. With this review we sought to give an insight on this sizable and complex topic, in order to get clearer ideas and a more precise reference about the diagnostic assessment and therapeutic management of HF and CKD.File | Dimensione | Formato | |
---|---|---|---|
2023 Heart Fail Rev (Assessment and management of HF in CKD).pdf
accesso aperto
Descrizione: Review
Tipologia:
Publisher's version/PDF
Dimensione
1.13 MB
Formato
Adobe PDF
|
1.13 MB | Adobe PDF | Visualizza/Apri |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.